Engflag

Anlam

Quick links to important sections

Anlam

Anlam_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anlam

Property Description
Active Ingredients Ambroxol, Levocetirizine, Montelukast
Form Oral Tablet (Fixed-Dose Combination)
Pharmacological Class Mucolytic, H₁ Antihistamine, Leukotriene Receptor Antagonist
Common Use Managing symptoms of allergic and respiratory conditions
Origin Synthetic Compound

What is the Pharmaceutical Identity of Anlam?

Anlam is classified as a Fixed-Dose Combination (FDC) product, defined as a medicine containing two or more active drugs in a single dosage form. It is a synthetically derived, triple-active preparation administered via the oral route as a solid tablet form. This intentional combination is developed to provide co-ordinated therapeutic activity from a single agent. The FDC nature of Anlam, incorporating three established compounds, is clinically recognized for streamlining the treatment of respiratory conditions that require multi-faceted pharmacological intervention.

Composition and Classification: The Triple-Action Profile

The active ingredients of Anlam are Ambroxol, Levocetirizine, and Montelukast (INN). The drug’s comprehensive action is derived from its three distinct pharmacological classes: Ambroxol functions as a mucolytic agent; Levocetirizine is a selective second-generation H₁ Antihistamine; and Montelukast belongs to the class of Leukotriene Receptor Antagonists (LTRA). Combination therapy involving a leukotriene modifier and an antihistamine is an established approach for persistent allergic conditions.

General Purpose: Why is Anlam Engineered as an FDC?

The fundamental general purpose of engineering Anlam as an FDC is to offer comprehensive management for complex respiratory tract disorders characterized by simultaneous airway congestion, excessive mucus production, and underlying allergic inflammation. By incorporating active ingredients that address three separate drivers—mucus viscosity, acute allergic response, and chronic inflammatory mediators—the preparation aims to achieve a synergistic therapeutic benefit that enhances airway clearance and helps reduce allergic and inflammatory irritation. The use of mucolytic agents, such as Ambroxol, is intended to assist in clearing thick respiratory secretions.

What side effects are possible with Anlam?

Possible Side Effects and Safety Information

The safety profile of Anlam, a combination containing Ambroxol, Levocetirizine, and Montelukast, is officially derived from the established regulatory data for its active components. Regulatory documents categorize adverse effects by their frequency and the system-organ class affected, such as the Nervous System and Gastrointestinal Disorders.

Commonly Documented Adverse Reactions

Adverse reactions classified as very common (1/10) or common (1/100) in official labeling include upper respiratory infection, headache, somnolence, fatigue, nausea, diarrhea, abdominal pain, and dry mouth.

Serious Adverse Reactions and Safety Warnings

The regulatory profile highlights rare but serious risks, including Severe Cutaneous Adverse Reactions (SCARs) such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The label also includes warnings for potential neuropsychiatric events, such as agitation, depression, and suicidal thoughts and behavior, primarily associated with the Montelukast component. Serious immunological reactions like anaphylaxis and angioedema are also documented.

Specific Safety Constraints

The official labeling includes specific safety considerations for patient populations with impaired organ function. Due to substantially reduced drug clearance, the medicine is officially contraindicated in individuals with end-stage renal disease. Caution is also required in individuals with severe hepatic impairment. Furthermore, specific safety notes exist for effects related to treatment duration, such as rare reports of severe itching (pruritus) following the long-term cessation of the Levocetirizine component.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose on the active ingredients of Anlam (Ambroxol, Levocetirizine, and Montelukast) may present with a combination of documented clinical signs affecting the CNS, GI system, and cardiovascular function. Documented overdose presentations include drowsiness (somnolence), headache, and psychomotor hyperactivity alongside nausea, vomiting, diarrhea, and abdominal pain. Symptoms consistent with known undesirable effects may also manifest, such as excessive saliva secretion (sialorrhea).

Emergency Actions and Severe Outcomes

The official regulatory guidance strictly mandates that immediate medical attention is required upon any suspicion of overdosage. Urgent help must be sought if the patient develops signs of extreme overdosage, such as hypotension, or severe neuropsychiatric events. The regulatory labeling notes that serious NP events, including suicidal thoughts and behavior, are reported risks associated with Montelukast exposure and necessitate immediate medical evaluation.

Treatment is required to be primarily symptomatic and supportive, as no specific antidote is known for the active ingredients. Acute measures like gastric lavage are not generally indicated unless the overdosage is extreme and very recent. For children, overdose may exhibit a distinct pattern, initially presenting with agitation and restlessness followed by drowsiness, a population-specific distinction noted in official labeling.

Therapeutic Uses of Anlam

What Anlam Treats: Main Uses and Benefits

Anlam is considered relevant in contexts involving heightened systemic burden for several respiratory and allergic conditions. The therapeutic approach of Anlam aligns with recognized principles of symptomatic relief. It is generally applied in contexts involving inflammatory or irritative states and symptoms that create noticeable physiological strain.

The medication is commonly used across conditions presenting with acute episodes, such as allergic rhinitis (seasonal and perennial), and conditions involving symptoms that create noticeable physiological strain, like bronchitis.

“This medication is applied across domains where additional symptomatic support is needed.”

Management and Support

Anlam is applied in situations requiring sustained symptomatic support for symptoms related to inflammatory or irritative states in the airways. It is relevant in clinical settings that involve symptoms related to physical discomfort from excessive mucus and related respiratory issues. It assists with maintaining functional stability when symptoms create noticeable physiological strain, helping patients cope more steadily with recurring manifestations.

Quick Fact: Relief for Complex Respiratory Discomfort
This combination is helpful in situations where multiple symptoms occur together, including nasal congestion, sneezing, and symptoms related to physical discomfort from excessive mucus.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Anlam — Official Regulatory Information

The eligibility profile for Anlam is defined by the combined regulatory restrictions of its three active components, establishing who is permitted to use the medicine and who is officially excluded.

Eligibility scope

  • Populations for whom use is allowed (as stated in label): Adults (18 years of age and older).
  • Populations for whom use is not recommended (if applicable): Pregnant women during the first trimester; breastfeeding women (use is prohibited); children younger than 15 years for the standard adult tablet.
  • Populations for whom use is contraindicated: Patients with known hypersensitivity to any component (including Cetirizine), End-Stage Renal Disease (Creatinine Clearance < 10 mL/min), and those experiencing an acute asthma attack. Use is also contraindicated in pediatric patients (6 months to 11 years) with impaired renal function.

Age-related eligibility rules: Safety and effectiveness are not established for infants younger than 6 months of age. Use in older adults (65 years and older) requires mandatory evaluation of renal function.

Condition-specific eligibility rules:

  • Renal Status: Use is restricted in moderate renal impairment; dose modification is required.
  • Comorbidities: Use requires caution in patients with a history of peptic ulceration or predisposing factors for urinary retention. The Montelukast component is restricted for allergic rhinitis in patients with an inadequate response to alternative treatments.

Eligibility classifications (high-level): Eligibility is strictly classified by regulators using terms such as "Contraindicated", "Not Recommended", and "Use Not Established" based on organ function, age thresholds, and reproductive status.

Connection to the overall eligibility profile: The official regulatory documentation structures eligibility by enforcing the most restrictive rules of the individual components. This results in definitive exclusion for populations with severe renal impairment and acute asthma attacks, while conditional eligibility applies to those with specific chronic conditions or moderate organ impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Contraindications and Restrictions

The regulatory label contraindicates Anlam in patients with severe renal impairment (creatinine clearance less than 10 mL/min) due to the expected risk of Levocetirizine metabolite accumulation. Official documentation also does not recommend co-administration with other cough suppressants, as this may lead to excessive sputum accumulation and potential airway obstruction. Patients with aspirin-sensitive asthma have the documented restriction to continue to avoid Non-Steroidal Anti-Inflammatory Agents (NSAIDs).

Pharmacokinetic and Exposure Effects

Substances affecting specific liver enzymes alter Montelukast exposure. The CYP inhibitor Gemfibrozil significantly increases the systemic exposure (AUC) of Montelukast by 4.4-fold. Conversely, co-administration with enzyme inducers like Phenobarbital may reduce Montelukast plasma levels. The Ambroxol component is documented to increase the concentration of certain antibiotics (e.g., doxycycline) within bronchopulmonary secretions.

Pharmacodynamic and Timing Constraints

Concurrent intake of alcohol or other CNS Depressants may result in an additive reduction in alertness. Regarding diagnostic procedures, a wash-out period of three days is required before allergy skin testing because the antihistamine component can inhibit the test results. Food decreases the rate of Levocetirizine absorption but does not reduce the overall amount absorbed.

Mechanism of Action

Anlam's mechanism involves the modulation of three distinct pharmacodynamic domains related to acute allergic signaling, chronic inflammatory pathways, and the physical properties of respiratory secretions.

Acute Signaling Inhibition at the H1 Receptor

This domain is mediated by Levocetirizine's selective inverse agonism at the Histamine H1 Receptor ( H1 R), a key target in the immediate histamine-mediated signaling cascade. This molecular blockade interrupts the rapid-onset cascade, resulting in reduced microvascular permeability and inhibition of histamine-induced plasma extravasation.

Chronic Modulation of the Leukotriene Inflammatory Pathway

Montelukast engages the chronic inflammatory component by acting as a selective competitive antagonist at the Cysteinyl Leukotriene Type 1 Receptor ( CysLT1 R). By blocking these receptors, the drug modulates the Arachidonic Acid Cascade, antagonizing the pro-inflammatory signaling and smooth muscle contraction typically mediated by leukotrienes.

Physicochemical Modification for Secretion Clearance

Ambroxol acts upon the mechanical and secretory pathways by stimulating Type II Pneumocytes to enhance the release of pulmonary surfactant. This increase in surfactant directly alters the rheology of respiratory secretions, substantially decreasing their surface tension and adhesiveness, which establishes conditions conducive to the natural mucociliary clearance process.

Dosage and Administration Information

Anlam is administered as a single, fixed-dose combination (FDC) tablet, containing Ambroxol 75 mg (Sustained-Release), Levocetirizine 5 mg, and Montelukast 10 mg. The designated route of administration for this preparation is oral.

The standardized regimen requires taking one tablet once daily. Due to the pharmacological profiles of its anti-allergic components, this daily dose is generally recommended for administration in the evening to support continuous management of symptoms.

Procedural and Contextual Instructions

For proper use, the tablet must be swallowed whole with an adequate amount of water. It is a mandatory procedural constraint that the tablet must not be crushed, chewed, or broken prior to swallowing, as this would compromise the function of the Ambroxol Sustained-Release component. The dose may be taken without regard to meals.

Anlam is strictly intended for sustained symptomatic management and is not indicated for the immediate reversal of sudden acute episodes or breathing crises. Patients are instructed to maintain the availability of their usual rescue medication. The fixed-dose strengths are generally intended for use in adults and adolescents aged 15 years and older. Dosage adjustments may be required in patients with pre-existing renal or hepatic impairment, based on the characteristics of the individual components.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Anlam

This overview summarizes the research that was studied for the combination of Ambroxol, Levocetirizine, and Montelukast, drawing on data from official sources and peer-reviewed scientific literature. The research describes the scope of studies that have examined populations characterized by both allergic inflammation and issues with mucus production.

Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

The evidence explored for the ingredients in conditions like allergic rhinitis includes data from short-term, randomized controlled trials (RCTs); these often focused on the two-drug combination. These studies were conducted during periods of increased symptom activity and were evaluated in adults and adolescents. Research examined outcomes related to physical discomfort such as nasal congestion, sneezing, and runny nose, which were measured using formal symptom scores.

However, the vast majority of high-level evidence available in systematic reviews is limited to the dual combination. The specific added role of the third component, Ambroxol, in combination for allergic rhinitis is not fully established in the same high-quality comparative studies.

Evidence for Use in Complex Respiratory Tract Disorders

The combination was studied for use in conditions involving periods of heightened symptoms related to inflammation and mucus issues. The research evaluated populations presenting with outcomes linked to inflammatory or irritative states alongside physical discomfort from excessive mucus. Studies primarily focused on clinical assessments related to airway clearance and changes in cough frequency.

Studies explored how the combination was observed in relation to the multiple factors involved in these conditions. Data collected primarily covers the short-term management of acute symptoms.

The Overall Evidence Landscape and Areas of Uncertainty

The overall evidence supporting the combination of active ingredients is associated with the body of research on the two-drug combination (Montelukast and Levocetirizine), where evidence quality appears to be Moderate. For the triple fixed-dose combination (FDC), evidence quality varies across studies, and certainty remains low for some of the complex indications. A key limitation is that comparative evidence is lacking from large-scale studies designed to evaluate differences against other therapeutic approaches.

Frequently Asked Questions (FAQ)

Common questions about Anlam (FAQ)

Q: What is the brand name of the drug discussed in the content?

A: The brand name used throughout this content is Anlam. According to official product information, this name refers to a fixed-dose combination containing Ambroxol, Levocetirizine, and Montelukast. Other fixed-dose combination products containing the same active ingredients may be marketed under different brand names globally.

Q: What are the symptoms of Levocetirizine metabolite accumulation?

A: Official reports on high exposure suggest that potential effects may include drowsiness in adults, and initial agitation or restlessness followed by drowsiness in children. This information is derived from the regulatory profile regarding the Levocetirizine component.

Q: Is there a restriction against Anlam use for breastfeeding or pregnant women?

A: Official labeling states that use of Anlam is generally not recommended for pregnant women because specific well-controlled studies for this combination have not been performed in this population. Official labeling also indicates that use in breastfeeding women is generally not recommended due to uncertainty regarding whether the active components are excreted into human breast milk.

Q: Are there any specific side effects or warnings for older adults (65 and over)?

A: Official guidelines for one component suggest that use in older adults (65 years and older) should be considered with a mandatory evaluation of renal function. This is necessary because one active ingredient is primarily eliminated by the kidneys, and renal function may be reduced in this population.

Q: What should a patient do if they miss a daily dose of Anlam?

A: Official patient information generally advises that a missed dose may be taken as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose should be skipped entirely. However, product labeling advises against taking a double dose to make up for a missed one.

Q: What should I do if I think I've taken too much Anlam?

A: Official regulatory information states that in the event of a suspected overdose, it is necessary to seek immediate medical attention. For guidance, patients may also contact a local Poison Control Center.

Q: Is the efficacy of Anlam supported by a systematic review?

A: Studies and official information indicate that the overall evidence quality for the three-drug Fixed-Dose Combination (FDC) varies across specific indications. For the related two-drug combination (Montelukast and Levocetirizine), evidence quality is often described as moderate and is found in systematic reviews of published research.

How should Anlam be stored and disposed of?

How to Store and Dispose of Anlam

Storage Requirements

The official labeling mandates that Anlam tablets must be stored at room temperature, typically specified as a temperature not exceeding 30 C or below 25 C. It is critical to protect the tablets from moisture and direct sunlight, which requires keeping the product in its original container and ensuring it is tightly closed.

Mandatory handling constraints include the instruction to keep the medicine out of the sight and reach of children and the explicit rule to not freeze the product.

Disposal Instructions

For disposal of expired or unused Anlam, the official protocol is to dispose of the unused medicine in accordance with local requirements.

Patients should consult a pharmacist or local waste authority for proper guidance, such as utilizing a drug take-back program. The medicine should generally not be flushed down the toilet and must be disposed of in a manner that ensures it is not consumed by pets or other people.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Anlam found in:

A-Z Index: